Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

BACKGROUND: Availability of checkpoint inhibitors has created a paradigm shift in the management of patients with solid tumors. Despite this, most patients do not respond to immunotherapy, and there is considerable interest in developing combination therapies to improve response rates and outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Charu, Prawira, Amy, Antonia, Scott, Rahma, Osama, Tolcher, Anthony, Cohen, Roger B, Lou, Yanyan, Hauke, Ralph, Vogelzang, Nicholas, P Zandberg, Dan, Kalebasty, Arash Rezazadeh, Atkinson, Victoria, Adjei, Alex A, Seetharam, Mahesh, Birnbaum, Ariel, Weickhardt, Andrew, Ganju, Vinod, Joshua, Anthony M, Cavallo, Rosetta, Peng, Linda, Zhang, Xiaoyu, Kaul, Sanjeev, Baughman, Jan, Bonvini, Ezio, Moore, Paul A, Goldberg, Stacie M, Arnaldez, Fernanda I, Ferris, Robert L, Lakhani, Nehal J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006844/
https://www.ncbi.nlm.nih.gov/pubmed/35414591
http://dx.doi.org/10.1136/jitc-2021-004424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006844/
https://www.ncbi.nlm.nih.gov/pubmed/35414591
http://dx.doi.org/10.1136/jitc-2021-004424

Ejemplares similares